Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 9;17(9):e0273723.
doi: 10.1371/journal.pone.0273723. eCollection 2022.

Colorectal cancers with a residual adenoma component: Clinicopathologic features and KRAS mutation

Hyoun Wook Lee  1 , Boram Song  2 , Kyungneun Kim  2
Affiliations

Colorectal cancers with a residual adenoma component: Clinicopathologic features and KRAS mutation

Hyoun Wook Lee et al. PLoS One. .

Abstract

Background/aim: Colorectal cancer is well known for its "adenoma-carcinoma" sequential carcinogenesis. Some colorectal cancers demonstrate a residual adenoma component during progression from adenoma to invasive carcinoma. However, the clinicopathological significance of residual adenoma component remains unclear. In this study, we aimed to investigate the clinicopathologic and molecular characteristics including the KRAS mutation in colorectal cancers containing a residual adenoma component.

Materials and methods: In this study, 498 surgically resected colorectal cancer patients were enrolled. Their detailed clinicopathologic features and results of molecular study including KRAS mutation test and microsatellite instability were analyzed.

Results: A residual adenoma component was identified in 42 (8.4%) patients with colorectal cancer. The presence of a residual adenoma component was associated with a high frequency of the KRAS mutation (65%, p = 0.031) as well as indolent clinicopathological features, including polypoid gross type (p < 0.001), well-differentiated histology (p < 0.001), low pT (p < 0.001) and pN stage (p = 0.003), absence of vascular invasion (p = 0.005), and a better progression-free prognosis (p = 0.029). The cases with an adenoma component had a 35.7% discordance rate on the KRAS mutation tests in their adenoma and carcinoma regions.

Conclusion: In conclusion, colorectal cancer with a residual adenoma component showed indolent clinicopathologic features and frequent KRAS mutations. Due to the discordance in the incidence of the KRAS mutation between the adenoma and carcinoma components, the adenoma component should be documented in the pathology report, and care should be taken not to include the adenoma component when collecting samples for molecular testing.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. The representative microscopic features of colorectal cancer with a residual adenoma component.
The remaining adenoma component is present on the left side of the invasive adenocarcinoma component (A). The adenoma component shows low-grade dysplasia without invasive epithelial islands or desmoplastic stroma (B).
Fig 2
Fig 2. The Kaplan-Meier survival curves based upon the presence of a residual adenoma component.
Patients with colorectal cancers that contained an adenoma component showed remarkably better progression-free (A) and overall (B) survival than those with no such component.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Al-Sohaily S, Biankin A, Leong R, Kohonen-Corish M, Warusavitarne J. Molecular pathways in colorectal cancer. J Gastroenterol Hepatol. 2012;27(9):1423–31. doi: 10.1111/j.1440-1746.2012.07200.x - DOI - PubMed
    1. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383(9927):1490–502. doi: 10.1016/S0140-6736(13)61649-9 - DOI - PubMed
    1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759–67. doi: 10.1016/0092-8674(90)90186-i - DOI - PubMed
    1. Smit WL, Spaan CN, Johannes de Boer R, Ramesh P, Martins Garcia T, Meijer BJ, et al.. Driver mutations of the adenoma-carcinoma sequence govern the intestinal epithelial global translational capacity. Proceedings of the National Academy of Sciences. 2020;117(41):25560–70. doi: 10.1073/pnas.1912772117 - DOI - PMC - PubMed
    1. Konishi K, Shen L, Jelinek J, Watanabe Y, Ahmed S, Kaneko K, et al.. Concordant DNA methylation in synchronous colorectal carcinomas. Cancer Prev Res (Phila). 2009;2(9):814–22. doi: 10.1158/1940-6207.CAPR-09-0054 - DOI - PMC - PubMed

Substances